Cargando…
T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody (mAb) rituximab to a range of standard therap...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351267/ https://www.ncbi.nlm.nih.gov/pubmed/37465110 http://dx.doi.org/10.3389/fonc.2023.1168622 |